ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.

Original reporting
Published Oct 27, 2026, 4:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 4:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study — source image
Decision brief

The 30-second read

$AVBPBullishMed
01

Why it matters

The disclosed response rates (44.8% overall) are higher than historical benchmarks for similar late‑line agents, potentially accelerating the path to a Phase III trial and attracting partnership interest.

02

Market read

First‑time release of promising Phase Ib data for a colorectal cancer ADC; likely to move AVBP and influence peer biotech valuations.

03

What to watch

The study size is small and follow‑up is short; competitive landscape in colorectal ADCs remains intense.

Relevance 9/10Novelty 9/10Timing: today

Background

ArriVent BioPharma (NASDAQ:AVBP) is a clinical‑stage company focused on precision oncology ADCs. The ARR‑217 candidate targets colorectal cancer, a market with unmet need in later lines of therapy.

Company-level read

Ticker impact

$AVBPBullishHigh confidence
Context

ArriVent BioPharma disclosed Phase Ib response rates of 44.8% overall, with detailed subgroup data, marking the first public release of these trial results.

Expected impact

likely upward pressure as the market prices in the encouraging response rates

Evidence & confidence

First-time disclosure of efficacy numbers for a late‑stage oncology ADC; such data historically moves small‑cap biotech stocks.

Market effects

May raise interest in ADC platforms and colorectal cancer therapeutics, prompting analysts to revisit peer biotech valuations.

US and China biotech investors could see heightened activity as the Phase Ib study enrolls in both regions.

Limited to oncology biotech niche; not a broad market driver.

Counterpoint

Early-phase data can be misleading; efficacy may not translate to later trials, and safety signals at higher doses could temper enthusiasm.

Key entities

  • ArriVent BioPharma

    Clinical‑stage biotech developing ADCs for oncology.

  • Bing Yao

    CEO of ArriVent, provided strategic commentary on trial plans.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPHighAI 9/10

ArriVent BioPharma Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.